Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05453877
Recruiting Observational

Clinical Indicators and Brain Image Data: a Study Based on Kailuan Cohort

NCT05453877 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Friendship Hospital
Phase
Observational
Started
2022-08-01
Last updated
2022-10-31

Condition(s) studied

Brain DiseasesHypertension

Investigational drug(s) / intervention(s)

No intervention will be applied.

No intervention will be applied.: This is an observational study.

Study summary

The investigators will analyze the relationship between the medical history, physiological indicators and the cerebral small vessel disease as well as the structural and functional changes of the brain/head and neck organs in a large sample size of subjects (participants), to identify the influencing factors of the occurrence and development of cerebral small vessel disease as well as the structural and functional changes of the brain/head and neck organs, so as to provide objective clues for early intervention of the disease and improve clinical outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age from 18 to 90 years old; 2. Comes from the Kailuan Cohort, completed ≥1 visits which the medical history, physiological indicators were measured; 3. Without contraindications of CT and MR scan; 4. Can cooperate with the measurement of the medical history, physiological indicators and brain imaging. Exclusion Criteria: 1. Known clinical history with congenital or acquired organic diseases (such as aortic stenosis); 2. Known history of drug abuse; 3. Pregnant and lactating women; 4. With clinical history of psychiatric diseases (such as schizophrenia).

Primary outcome measure(s)

  • White matter hyperintensity of the brain measured by MRI (magnetic resonance imaging) — every two years up to 30 years
  • microbleeds of the brain measured by MRI (magnetic resonance imaging) — every two years up to 30 years
  • Lacunes of the brain measured by MRI (magnetic resonance imaging) — every two years up to 30 years
  • Cerebral blood flow measured by MRI (magnetic resonance imaging) — every two years up to 30 years
  • Brain volume measured by MRI (magnetic resonance imaging) — every two years up to 30 years
  • White matter microstructural integrity of the brain measured by MRI (magnetic resonance imaging) — every two years up to 30 years

Trial sites (2)

FacilityCityRegionStatus
Beijing Friendship Hospital, Capital Medical University Beijing Beijing Municipality Not Yet Recruiting
Kailuan General Hospital Tangshan Hebei Recruiting

More Beijing Friendship Hospital trials in China

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity Starting soon
Rivaroxaban in Idiopathic Membranous Nephropathy Recruiting
Adverse Cardiovascular Events During Painless Gastroscopy Diagnosis and Treatment in Elderly Frail Patients Recruiting
Eye-Brain-Kidney in CKD Recruiting
Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections Starting soon

Other trials for the same condition

The Effect of Ablation Duration of Renal Denervation on Antihypertensive Efficacy Recruiting
EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure Starting soon
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia Enrolling by invitation
Sympathetic Mapping/ Ablation of Renal Nerves Trial Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05453877 on ClinicalTrials.gov ↗ ← All trials in China